Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells

• Published in: Journal of ethnopharmacology 2023-01, Vol.301, p.115815-115815, Article 115815
• Main Authors: Lan, Xiaoying, Hu, Min, Jiang, Liling, Wang, Jiamin, Meng, Yi, Chen, Xinmei, Liu, Aochu, Ding, Wa, Zhang, Haichuan, Zhou, Huan, Liu, Bingyuan, Peng, Guanjie, Liao, Siyan, Chen, Xin, Liu, Jinbao, Shi, Xianping
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Apoptosis; Bcr-abl; Biological Products - therapeutic use; Cell Line, Tumor; Cell Proliferation; CML; Deubiquitinating Enzymes - therapeutic use; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl - genetics; Humans; Imatinib Mesylate - pharmacology; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Mice; Piperlongumine; Proteasome; Proteasome Endopeptidase Complex - metabolism; Ubiquitin Thiolesterase - therapeutic use; UCHL5; USP14
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2022.115815

Piper longum L., an herbal medicine used in India and other Asian countries, is prescribed routinely for a range of diseases, including tumor. Piperlongumine, a natural product isolated from Piper longum L., has received widespread attention due to its various pharmacological activities, such as anti-inflammatory, antimicrobial, and antitumor effects. Chronic myelogenous leukemia (CML) is a hematopoietic disease caused by Bcr-Abl fusion gene, with an incidence of 15% in adult leukemias. Targeting Bcr-Abl by imatinib provides a successful treatment approach for CML. However, imatinib resistance is an inevitable issue for CML treatment. In particular, T315I mutant is the most stubborn of the Bcr-Abl point mutants associated with imatinib resistance. Therefore, it is urgent to find an alternative approach to conquer imatinib resistance. This study investigated the role of a natural product piperlongumine in overcoming imatinib resistance in CML. Cell viability and apoptosis were evaluated by MTS assay and Annexin V/propidium iodide counterstaining assay, respectively. Levels of intracellular signaling proteins were assessed by Western blots. Mitochondrial membrane potential was reflected by the fluorescence intensity of rhodamine-123. The function of proteasome was detected using 20S proteasomal activity assay, proteasomal deubiquitinase activity assay, and deubiquitinase active-site-directed labeling. The antitumor effects of piperlongumine were assessed with mice xenografts. We demonstrate that (i) Piperlongumine inhibits proteasome function by targeting 20S proteasomal peptidases and 19S proteasomal deubiquitinases (USP14 and UCHL5) in Bcr-Abl-WT and Bcr-Abl-T315I CML cells; (ii) Piperlongumine inhibits the cell viability of CML cell lines and primary CML cells; (iii) Proteasome inhibition by piperlongumine leads to cell apoptosis and downregulation of Bcr-Abl; (iv) Piperlongumine suppresses the tumor growth of CML xenografts. These results support that blockade of proteasome activity by piperlongumine provides a new therapeutic strategy for treating imatinib-resistant CML. [Display omitted] •Piperlongumine exhibits potent anti-cancer activities in CML in vitro and in vivo.•Piperlongumine inhibits activities of 20S proteasome, USP14, and UCHL5.•Piperlongumine induces apoptosis and suppresses Bcr-Abl signaling in CML cells.•Proteasome inhibition as potential approach for overcoming imatinib resistance.